EA201590062A1 - Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью - Google Patents

Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью

Info

Publication number
EA201590062A1
EA201590062A1 EA201590062A EA201590062A EA201590062A1 EA 201590062 A1 EA201590062 A1 EA 201590062A1 EA 201590062 A EA201590062 A EA 201590062A EA 201590062 A EA201590062 A EA 201590062A EA 201590062 A1 EA201590062 A1 EA 201590062A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iron
increase
patients
reduce
chronic
Prior art date
Application number
EA201590062A
Other languages
English (en)
Inventor
Энрике Порадосу
Рон Бентсур
Джеймс Ф. Оливьеро III
Original Assignee
Керикс Байофармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Керикс Байофармасьютикалз, Инк. filed Critical Керикс Байофармасьютикалз, Инк.
Publication of EA201590062A1 publication Critical patent/EA201590062A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Раскрыты способы введения лимонно-кислого железа для уменьшения и/или контроля уровня фосфора в крови, увеличения уровней бикарбоната в сыворотке, повышения одного или нескольких параметров накопления железа (например, увеличение концентрации ферритина в сыворотке крови, увеличение насыщения трансферрина (TSAT), увеличение концентрации гемоглобина), увеличения усвоения железа, поддержания запасов железа в организме, лечения дефицита железа, лечения анемии, снижения потребности в железе IV и/или снижения потребности в эритропоэз-стимулирующих веществах (ESA) у пациентов с хронической почечной недостаточностью.
EA201590062A 2012-06-21 2013-06-21 Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью EA201590062A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15
PCT/US2013/047134 WO2013192565A2 (en) 2012-06-21 2013-06-21 Use of ferric citrate in the treatment of chronic kidney disease patients

Publications (1)

Publication Number Publication Date
EA201590062A1 true EA201590062A1 (ru) 2016-02-29

Family

ID=49769729

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590062A EA201590062A1 (ru) 2012-06-21 2013-06-21 Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью

Country Status (17)

Country Link
US (3) US20130345303A1 (ru)
EP (3) EP3730136B1 (ru)
JP (4) JP2015535209A (ru)
KR (2) KR20200103855A (ru)
CN (2) CN104884055A (ru)
AU (2) AU2013278000A1 (ru)
BR (1) BR112014032049A2 (ru)
CA (1) CA2876982A1 (ru)
DK (1) DK3730136T3 (ru)
EA (1) EA201590062A1 (ru)
ES (2) ES2970050T3 (ru)
HK (2) HK1210013A1 (ru)
IL (1) IL236356A0 (ru)
MX (1) MX2014015615A (ru)
PL (1) PL3730136T3 (ru)
SG (2) SG11201408521WA (ru)
WO (1) WO2013192565A2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938585A (zh) 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
ES2646271T3 (es) 2013-06-05 2017-12-13 Tricida Inc. Polímeros de unión de protones para la administración oral
ES2856261T3 (es) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Método y aparatos para determinar una pérdida diaria de hierro de un paciente
CA2928200A1 (en) * 2013-11-04 2015-05-07 Keryx Biopharmaceuticals, Inc. Ferric citrate for reducing cardiac failure in chronic kidney disease patients
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
WO2016141124A1 (en) * 2015-03-04 2016-09-09 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of iron-deficiency anemia
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
JP7387435B2 (ja) 2017-09-19 2023-11-28 日本たばこ産業株式会社 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用
AU2018360867A1 (en) 2017-11-03 2020-04-30 Tricida, Inc. Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
JP2022505697A (ja) * 2018-10-29 2022-01-14 ファーマコスモス ホールディング エー／エス カルボキシマルトース第二鉄による鉄欠乏症の治療
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180094B1 (en) * 1996-07-19 2001-01-30 Nikken Chemicals Co., Ltd. Remedies for hyperphosphatemia
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
MX2008002360A (es) 2005-08-18 2008-04-29 Globoasia Llc Compuestos organicos ferricos grado farmaceutico, uso de los mismos y metodos para elaborar los mismos.
CA2635894C (en) * 2006-01-06 2017-09-12 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
ES2580127T3 (es) 2006-01-30 2016-08-19 Panion & Bf Biotech Inc. Procedimiento de tratamiento de la nefropatía crónica
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型

Also Published As

Publication number Publication date
JP2015535209A (ja) 2015-12-10
WO2013192565A3 (en) 2015-10-15
KR20200103855A (ko) 2020-09-02
SG10201805177PA (en) 2018-07-30
ES2796254T3 (es) 2020-11-26
HK1214503A1 (zh) 2016-07-29
SG11201408521WA (en) 2015-01-29
AU2013278000A1 (en) 2015-01-22
DK3730136T3 (da) 2024-01-22
KR102150135B1 (ko) 2020-08-31
JP2018138562A (ja) 2018-09-06
JP2022070945A (ja) 2022-05-13
EP2863906A2 (en) 2015-04-29
EP2863906B1 (en) 2020-03-18
PL3730136T3 (pl) 2024-03-25
US20140234416A1 (en) 2014-08-21
MX2014015615A (es) 2015-03-20
KR20150036131A (ko) 2015-04-07
BR112014032049A2 (pt) 2017-07-25
US20150079168A1 (en) 2015-03-19
IL236356A0 (en) 2015-02-26
WO2013192565A2 (en) 2013-12-27
ES2970050T3 (es) 2024-05-24
AU2018203205A1 (en) 2018-05-31
JP2020100638A (ja) 2020-07-02
HK1210013A1 (en) 2016-04-15
EP4335436A3 (en) 2024-05-15
US20130345303A1 (en) 2013-12-26
AU2018203205B2 (en) 2020-03-12
EP3730136B1 (en) 2023-12-27
CN113244209A (zh) 2021-08-13
EP4335436A2 (en) 2024-03-13
CN104884055A (zh) 2015-09-02
EP3730136A1 (en) 2020-10-28
CA2876982A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
EA201590062A1 (ru) Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью
MX2016005734A (es) Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica.
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
WO2013132498A3 (en) Inhalation of nitric oxide for treating respiratory diseases
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
WO2009125300A3 (en) Oxygenation procedures for newborns and devices for use therein
MX2016016531A (es) Metodos y composiciones para el tratamiento de las ulceras.
MX2014011186A (es) Metodo para mejorar la eficiencia de las transfusiones de sangre.
EA201492106A1 (ru) Способ и устройство для контроля экстракорпоральной обработки крови пациента
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
MX361881B (es) Prediccion y optimizacion de terapia de potasio en suero para terapia de sangre para insuficiencia renal, especialmente hemodialisis domiciliaria.
EA201990403A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
WO2012058585A3 (en) Treatment of heart failure with natriuretic peptides
BR112013009660A8 (pt) Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante
BR112014009414A2 (pt) uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos
WO2013142153A3 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
WO2014049438A3 (en) Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof
UA62757U (ru) Способ прогнозирования адекватности программного гемодиализа у больных с хронической болезнью почек v стадии
UA58034U (ru) Способ оценки риска развития осложнений течения хронической болезни почек у больных, которых лечат программным гемодиализом
NZ725920A (en) Use of ferric citrate in the treatment of chronic kidney disease patients
UA80889U (ru) Способ дифференциальной диагностики анемий у больных с хроническими заболеваниями внутренних органов
RU2013110191A (ru) Способ определения предикторной значимости мозгового натрийуретического пептида у больных хронической болезнью почек, получающих терапию программным гемодиализом
范凯文 et al. A study of effects of using low dialysate calcium concentration (1.50 mmol/L) on blood pressure, serum concentrations of calcium, parathyroid hormone and aldosterone in chronic hemodialysis patients